Mereo BioPharma Group plc (MREO)

NASDAQ: MREO · IEX Real-Time Price · USD
3.760
-0.220 (-5.53%)
At close: Jun 24, 2024, 4:00 PM
3.810
+0.050 (1.33%)
After-hours: Jun 24, 2024, 7:05 PM EDT
-5.53%
Market Cap 555.32M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 147.69M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 743,383
Open 4.000
Previous Close 3.980
Day's Range 3.700 - 4.050
52-Week Range 1.070 - 4.500
Beta 0.71
Analysts Strong Buy
Price Target 7.50 (+99.47%)
Earnings Date May 15, 2024

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 33
Stock Exchange NASDAQ
Ticker Symbol MREO
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for MREO stock is "Strong Buy." The 12-month stock price forecast is $7.5, which is an increase of 99.47% from the latest price.

Price Target
$7.5
(99.47% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the ...

10 days ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

25 days ago - GlobeNewsWire

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its f...

5 weeks ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

2 months ago - GlobeNewsWire

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively

3 months ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

3 months ago - GlobeNewsWire

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...

6 months ago - GlobeNewsWire

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an up...

8 months ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced tha...

9 months ago - GlobeNewsWire

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...

10 months ago - GlobeNewsWire

Mereo BioPharma to Present at the Jefferies Healthcare Conference

LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

1 year ago - GlobeNewsWire

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that ...

1 year ago - GlobeNewsWire

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

1 year ago - GlobeNewsWire

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

LONDON, May 05, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that ...

1 year ago - GlobeNewsWire

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its...

1 year ago - GlobeNewsWire

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU

1 year ago - GlobeNewsWire

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today a...

1 year ago - GlobeNewsWire

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today ...

1 year ago - GlobeNewsWire

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Mereo to Appoint Four New Directors to its Board of Directors

1 year ago - GlobeNewsWire

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today ...

1 year ago - GlobeNewsWire

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Reiterates Quality and Composition of Mereo's Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo's Strategy and Maximize Shareholder Value

1 year ago - GlobeNewsWire

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group...

1 year ago - Business Wire

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones

1 year ago - GlobeNewsWire

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Designation Validates Alvelestat's Potential to Address a Serious Unmet Need

1 year ago - GlobeNewsWire

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Rubric has Rejected Mereo's Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo's Board

1 year ago - GlobeNewsWire